XML 42 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
 1 Months Ended 6 Months Ended
Apr. 05, 2016
May 31, 2016
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2014
Sep. 23, 2014
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Accumulated deficit     $ (2,918,060,000)   $ (2,863,229,000)    
Number of shares sold in underwritten public offering   48,543,692          
Proceeds from offering of common stocks and warrants, net   $ 47,400,000 734,000 $ 12,820,000      
Cash and cash equivalents     63,733,000 $ 107,187,000 $ 59,074,000 $ 120,841,000  
Amount available for future borrowings     $ 30,100,000        
License and Collaboration Agreement with Sanofi              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Profits and losses sharing percentage 35.00%   35.00%        
Maximum secured loan facility             $ 175,000,000
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Profits and losses sharing percentage 65.00%   65.00%        
Maximum secured loan facility     $ 175,000,000        
Maximum              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Number of warrants available for purchase common shares   48,543,692          
Senior convertible notes due December 31, 2019 | Deerfield | Minimum | Less portion of commitment asset              
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]              
Available amount of credit facility under covenant restrictions     $ 25,000,000